Back to Search
Start Over
Alternative splicing as a biomarker and potential target for drug discovery
- Source :
- Acta Pharmacologica Sinica. 36:1212-1218
- Publication Year :
- 2015
- Publisher :
- Springer Science and Business Media LLC, 2015.
-
Abstract
- Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates that approximately 95% of human genes with multiple exons undergo alternative splicing during pre-mRNA maturation. Thus, alternative splicing plays a critical role in physiological processes and cell development programs, and.dysregulation of alternative splicing is highly associated with human diseases, such as cancer, diabetes and neurodegenerative diseases. In this review, we discuss the regulation of alternative splicing, examine the relationship between alternative splicing and human diseases, and describe several approaches that modify alternative splicing, which could aid in human disease diagnosis and therapy.
- Subjects :
- Genetic Markers
Pharmacology
Genetics
Drug discovery
Alternative splicing
Neurodegenerative Diseases
Review
General Medicine
Biology
Biomarker (cell)
Alternative Splicing
Diabetes mellitus genetics
Exon
Neoplasms
Drug Discovery
Gene expression
Diabetes Mellitus
Animals
Humans
Pharmacology (medical)
Human genome
Molecular Targeted Therapy
RNA, Messenger
Gene
Subjects
Details
- ISSN :
- 17457254 and 16714083
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Acta Pharmacologica Sinica
- Accession number :
- edsair.doi.dedup.....f2bfce9c0de4a57ac0d7dc803bd350c8
- Full Text :
- https://doi.org/10.1038/aps.2015.43